India’s New Pharmaceutical & Biotech Patent Guidelines (2026): What Companies Need to Know
India’s pharmaceutical and biotech patent landscape may be entering a new phase. On 4 September 2026, the Office of the Controller General of Patents, Designs and Trademarks (CGPDTM) published two sets of draft examination guidelines:
- Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals (2026)
- Draft Guidelines for Examination of Patent Applications in the Field of Biotechnology (2026)
Stakeholders are invited to submit comments and suggestions within 15 days of publication, i.e., on or before 19 September 2026, via email to: cgoffice.in@gov.in and llc-ipo@gov.in.
For pharma and biotech companies, this is more than a procedural update. The proposed guidelines could influence how patent applications are examined and how applicants approach issues such as novelty, inventive step, Section 3(d), prior-art searches, claim drafting, disclosure, and (for biotech) gene-editing, bioinformatics, and biodiversity compliance.
So, what should innovators be paying attention to?
Why Are the New Guidelines Important?
Pharmaceutical and biotech applications often involve highly technical inventions from new chemical entities, formulations, polymorphs, salts, combinations, and dosage forms to manufacturing processes, genetic constructs, CRISPR-based methods, and synthetic biology platforms.
Because these inventions can build upon existing knowledge, determining what is genuinely new and inventive is challenging. The draft guidelines aim to provide greater clarity and consistency to examiners when assessing such applications.
For applicants, that means patent strategy needs to be considered earlier in the R&D process, with stronger alignment between experimental data, technical advantages, and claim scope.
What the Guidelines Do (and Don’t) Change
These are examination guidelines, not new law.
They do:
- Provide updated guidance to examiners on assessing pharma and biotech applications under the existing Patents Act and Rules.
- Clarify the IPO’s current approach to novelty, inventive step, Section 3(d) (for pharma), sufficiency of disclosure, clarity, and support of claims.
- Incorporate recent case law and developments in pharmaceutical/biotech technologies (including CRISPR, bioinformatics, and synthetic biology) into the examination framework.
They do not:
- Amend or replace the Indian Patents Act, 1970, the Patent Rules, or binding court judgments.
- Create new statutory requirements; they interpret and operationalize the existing legal framework for examiners and applicants.
In short: the guidelines shape how applications are examined, not what the law says.
Section 3(d) Remains a Major Consideration (Pharma)
Section 3(d) of the Indian Patents Act continues to be one of the most important considerations in pharmaceutical patenting, especially where an invention relates to a new form or derivative of a known substance.
Simply showing a new characteristic may not be enough; applicants may need to establish the required enhancement in efficacy. This is particularly important for:
- Polymorphs
- Salts and derivatives
- Isomers
- Particle-size variants
- New forms of known substances
- Pharmaceutical combinations (with an important nuance, below)
Section 3(d) and “Combinations”: An Important Nuance
The guidelines discuss pharmaceutical combinations, but recent case law suggests a key distinction:
- Section 3(d)’s “combination” explanation is primarily directed at combinations of derivatives or closely related forms of a single known substance.
- Combinations of two or more independent APIs with distinct chemical structures and mechanisms may be assessed differently; Section 3(d) may not apply in the same way as it does to new forms of a single known compound.
Practical takeaway:
- If your invention is a new form/derivative of one known substance, plan early for Section 3(d) analysis and efficacy data.
- If your invention is a multi-API combination, still evaluate Section 3(d) carefully, but also focus on inventive step, synergy, unexpected technical effects, and clinical/experimental evidence distinguishing the combination from prior art.
What’s New in the Biotech Guidelines?
The Draft Biotechnology Guidelines (2026) update the 2013 version to reflect advances such as:
- CRISPR-Cas9 and other gene-editing technologies
- Bioinformatics and sequence-analysis tools
- Synthetic biology and engineered biological systems
- Updated search tools and databases for biotech prior art
- Expanded guidance on biodiversity compliance and related requirements (e.g., source/geographical origin of biological material)
For biotech innovators, this means earlier attention to:
- Sequence listings and data standards
- Enablement and support for broad biotech claims
- Documentation of technical effects and experimental evidence
- Compliance with access-and-benefit-sharing and origin-disclosure obligations where relevant
Prior-Art Searching Could Become Even More Critical
The draft guidelines discuss multiple prior-art search strategies, including searches based on:
- Chemical structures
- Molecular formulas
- IUPAC names
- CAS numbers
- Generic names
- Patent classifications
This is especially relevant in pharma/biotech, where the same compound or technology can appear under different names across scientific literature and patent databases.
A comprehensive search before filing can help companies:
- Identify potential patentability problems
- Understand competitors’ patent positions
- Draft stronger, more defensible claims
- Avoid unnecessary prosecution costs
- Identify opportunities for differentiated innovation
In other words, the best time to discover a patent problem is before filing, not after receiving an examination report.
Strong Disclosure Matters
Pharmaceutical and biotech inventions often depend heavily on experimental evidence and technical data. The proposed guidelines emphasise:
- Sufficiency of disclosure
- Clarity of claims
- Support of claims by the specification
This reinforces an important principle: broad claims are not automatically better claims. A patent should provide enough technical information to support what is being claimed. For pharma/biotech inventions, this makes the relationship between R&D data and patent drafting especially important.
Patent teams should therefore work closely with researchers to ensure that relevant experimental results, technical advantages, and supporting information are properly captured.
What Should Pharma & Biotech Companies Do Now?
Although these are still draft guidelines, companies can use this moment to review their IP strategy.
Businesses developing pharmaceutical or biotech innovations should consider:
- Reviewing pending applications against the proposed examination approach.
- Strengthening prior-art searches before filing new applications.
- Documenting experimental and efficacy data carefully.
- Reviewing Section 3(d) risks at an early stage (for pharma).
- Checking whether claims are adequately supported by the specification.
- Evaluating follow-on innovations and potential patent opportunities.
- Providing feedback during the consultation process, where appropriate.
The consultation phase also gives industry an opportunity to highlight practical concerns before the guidelines are finalised.
How to Submit Comments (and By When)
- Deadline: 15 days from 4 September 2026 → 19 September 2026.
- Email addresses:
cgoffice.in@gov.in
llc-ipo@gov.in (note: llc-ipo, not llc-dpo).
What Does This Mean for the Future of Pharma & Biotech IP in India?
India has long balanced two objectives: encouraging genuine pharmaceutical and biotech innovation while preventing weak or repetitive patent claims from unnecessarily extending exclusivity. The new draft guidelines are part of that larger conversation.
For innovators, the takeaway is not simply to “file more patents.” It is to build better, evidence-backed, and commercially meaningful patent strategies. A strong pharma/biotech patent begins well before the application reaches the Patent Office, often in the R&D lab, during prior-art research, and through early collaboration between scientists and IP professionals.
As the proposed guidelines develop, companies that understand these changes early will be better positioned to protect their innovations and navigate examination more effectively.
